Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 8/31/2023 | 5/31/2022 | 5/31/2021 | |
|---|---|---|---|---|
| Revenue | £2,739 | £1,152 | £3,859 | £3,722 |
| % Growth | 137.8% | -70.1% | 3.7% | – |
| Cost of Goods Sold | £1,508 | £360 | £2,402 | £865 |
| Gross Profit | £1,231 | £792 | £1,457 | £2,857 |
| % Margin | 44.9% | 68.8% | 37.8% | 76.8% |
| R&D Expenses | £0 | £1,255 | £1,517 | £1,615 |
| G&A Expenses | £1,696 | £434 | £7,052 | £5,652 |
| SG&A Expenses | £1,696 | £3,779 | £7,052 | £5,652 |
| Sales & Mktg Exp. | £0 | £3,345 | £0 | £0 |
| Other Operating Expenses | £2,761 | £0 | £1,474 | £1,046 |
| Operating Expenses | £4,457 | £5,034 | £10,043 | £8,002 |
| Operating Income | -£3,226 | -£4,242 | -£8,586 | -£5,145 |
| % Margin | -117.8% | -368.2% | -222.5% | -138.2% |
| Other Income/Exp. Net | -£749 | -£1,686 | -£943 | -£551 |
| Pre-Tax Income | -£3,975 | -£5,928 | -£9,529 | -£5,696 |
| Tax Expense | -£477 | £223 | -£17 | -£1,068 |
| Net Income | -£3,628 | £4,104 | -£9,512 | -£4,628 |
| % Margin | -132.5% | 356.3% | -246.5% | -124.3% |
| EPS | -0.049 | 0.057 | -0.15 | -0.072 |
| % Growth | -186.4% | 137.7% | -109.2% | – |
| EPS Diluted | -0.049 | 0.057 | -0.15 | -0.072 |
| Weighted Avg Shares Out | 74,142 | 72,509 | 64,547 | 64,571 |
| Weighted Avg Shares Out Dil | 74,142 | 72,509 | 64,547 | 64,571 |
| Supplemental Information | – | – | – | – |
| Interest Income | £17 | £204 | £0 | £403 |
| Interest Expense | £711 | £2,004 | £943 | £954 |
| Depreciation & Amortization | £263 | £981 | £197 | £740 |
| EBITDA | -£3,001 | -£4,431 | -£8,389 | -£4,002 |
| % Margin | -109.6% | -384.6% | -217.4% | -107.5% |